With $65 million under management, AgeChem Fund L.P. seeks to build a portfolio of companies focused on developing novel therapeutics for a wide range of age-related diseases, including metabolic disorders, cardiovascular diseases, cancers, diseases of the central nervous system, inflammatory diseases, ophthalmic diseases, and more.